Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Sk°yen
0213 Oslo

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo

Tel:  +47 21 07 81 60

New search    Hide text from Guidelines


This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.


Combination products are classified in L01XY - Combinations of antineoplastic agents, except for combinations of monoclonal antibodies or antibody drug conjugates which are classified in L01FY.
Detoxifying agents used in connection with high dose treatment of antineoplastic agents are classified in V03AF (e.g. calcium folinate).
Radiopharmaceuticals used in the treatment of cancer are classified in V10X.

DDDs have been established for the protein kinase inhibitors in L01E only.
No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X. This is because of highly individualised use and wide dosage ranges. The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.
The consumption of antineoplastic agents is in some countries measured in grams. This is recommended as a method to be used internationally for these particular agents.


This group comprises protein kinase inhibitors used for neoplastic diseases. Substances are classified according to their main target.

Substances which are multi-targeted without a clear main target are classified in L01EX.
Lipid kinase inhibitors (phosphatidylinositol-3-kinase (Pi3K) inhibitors) are classified in L01EM.

L01EX Other protein kinase inhibitors

This group comprises other protein kinase inhibitors which cannot be classified in the preceding groups. Substances which are multi-targeted without a clear main target are also classified in this group.

The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.
The DDD for lenvatinib is based on the treatment of renal cell carcinoma.
The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).

    ATC code  Name  DDD  U Adm.R Note
    L01EX11 quizartinib    

List of abbreviations

Last updated: 2024-01-26